🟢 Femasys is trading 7.17% up in pre-market after UNC Health deal to distribute fertility products

Femasys is trading at $2.99, up 7.17% in pre-market on August 28, 2026, following its partnership with UNC Health to distribute FemVue, SpermVue, and FemaSeed Complete across OB/GYN locations.

• The collaboration expands access to fertility diagnostics.
• It positions FemaSeed Complete as a first-line treatment option.
• Broader markets are relatively subdued, making the partnership the clearest available catalyst.